<DOC>
	<DOCNO>NCT01608295</DOCNO>
	<brief_summary>The purpose study examine effect vilazodone treatment depression old adult .</brief_summary>
	<brief_title>Vilazodone Treatment Geriatric Depression</brief_title>
	<detailed_description>This 12-week double-blind comparison novel antidepressant , vilazodone , gold-standard drug , paroxetine , treatment geriatric depression . We interested assess difference response vilazodone ( VLZ ) compare paroxetine ( PAR ) . We hope detect difference response primary outcome ( depressed mood ) secondary outcome cognition . We seek examine directly 80 old adult ( 60 year age old ) major depression anticipate 60 completers . This propose trial serve pilot study estimate efficacy tolerability drug old depressed adult , use project dose-finding population .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>60 year age older The presence major depressive disorder diagnose accord DSMIV criteria A 24item Hamilton Rating Scale Depression ( HAMD ) score 17 high baseline MiniMental State Exam ( MMSE ) score &gt; 24 . Subjects exclude current and/or lifetime history psychiatric disorder ( except unipolar depression without comorbid generalize anxiety disorder ) , recent unstable medical neurological disorder ; disability prevent participation study ; diagnosis MCI/ dementia ; know allergic reaction paroxetine vilazodone .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>depressed</keyword>
	<keyword>geriatric</keyword>
	<keyword>old adult</keyword>
	<keyword>antidepressant</keyword>
	<keyword>depression</keyword>
	<keyword>anxious</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>MDD</keyword>
</DOC>